doi: 10.1161/01.RES.0000259591.97107.6c
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Reviews |
Defective Mitochondrial Biogenesis
A Hallmark of the High Cardiovascular Risk in the Metabolic Syndrome?
From the Department of Pharmacology, Chemotherapy and Medical Toxicology (E.N., M.O.C.), School of Medicine, Milan University, Italy; Istituto Auxologico Italiano (E.N., M.O.C.), Italy; Department of Preclinical Sciences (E.C.), Laboratorio Interdisciplinare Tecnologie Avanzate Vialba, Milan University, Italy; E. Medea Scientific Institute (E.C.), Bosisio Parini, Italy; and The Wolfson Institute for Biomedical Research (S.M.), University College London, UK.
Correspondence to Enzo Nisoli, MD, PhD, Department of Pharmacology, Chemotherapy and Medical Toxicology, School of Medicine, Milan University, Via Vanvitelli, 32-20129 Milan, Italy; E-mail enzo.nisoli{at}unimi.it; or Salvador Moncada, FRCP, FRS, Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, UK; E-mail: s.moncada@ucl.ac.uk
This Review is part of a thematic series on the Role of Mitochondria in Cardiovascular Diseases, which includes the following articles:
Defective Mitochondrial Biogenesis: A Hallmark of the High Cardiovascular Risk in the Metabolic Syndrome?
Mitochondrial Dysfunction in Atherosclerosis
Free Radicals, Mitochondria, and Oxidized Lipids: The Emerging Role in Signal Transduction in Vascular Cells
Mitochondrial Biology and Vascular Biology
Role of Mitochondria in Insulin Resistance
Marshall S. Runge Guest Editor
 |
Abstract |
|---|
Top
Abstract
IntroductionThe metabolic syndrome is a group of risk factors of metabolic origin that are accompanied by increased risk for type 2 diabetes mellitus and cardiovascular disease. These risk factors include atherogenic dyslipidemia, elevated blood pressure and plasma glucose, and a prothrombotic and proinflammatory state. The condition is progressive and is exacerbated by physical inactivity, advancing age, hormonal imbalance, and genetic predisposition. The metabolic syndrome is a particularly challenging clinical condition because its complex molecular basis is still largely undefined. Impaired cell metabolism has, however, been suggested as a relevant pathophysiological process underlying several clinical features of the syndrome. In particular, defective oxidative metabolism seems to be involved in visceral fat gain and in the development of insulin resistance in skeletal muscle. This suggests that mitochondrial function may be impaired in the metabolic syndrome and, thus, in the consequent cardiovascular disease. We have recently found that mitochondrial biogenesis and function are enhanced by nitric oxide in various cell types and tissues, including cardiac muscle. Increasing evidence suggests that this mediator acts as a metabolic sensor in cardiomyocytes. This implies that a defective production of nitric oxide might be linked to dysfunction of the cardiomyocyte metabolism. Here we summarize some recent findings and propose a hypothesis for the high cardiovascular risk linked to the metabolic syndrome.
Key Words: nitric oxide • mitochondrial biogenesis • peroxisome proliferator-activated receptor-
coactivator 1
• cardiomyocytes • obesity
|
Introduction |
|---|
The metabolic syndrome is a term applied to a pattern of metabolic risk factors occurring concurrently; these include atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, and a prothrombotic and proinflammatory state.1,2 The dominant underlying risk factors appear to be abdominal obesity and insulin resistance. With aging and increasing obesity, the incidence and severity of these risk factors of metabolic and cardiovascular origin increase dramatically, as does the risk of atherosclerotic cardiovascular disease and its complications.3–6 If atherosclerotic cardiovascular disease does develop, cardiovascular complications—cardiac arrhythmias, heart failure, and thrombotic episodes—often ensue. Many individuals affected by the metabolic syndrome eventually develop type 2 diabetes mellitus. Once diabetes develops, a host of complications, including renal failure and diabetic cardiomyopathy and neuropathies, can be observed; and when atherosclerotic cardiovascular disease and diabetes exist concomitantly, the risk of subsequent cardiovascular morbidity is very high.1
The multiple aspects of the metabolic syndrome have suggested the coexistence of complex, multiorgan pathophysiological events, with the development of specific organ diseases characteristically linked to each other.2–6 At the cellular level, various pathophysiological events responsible for the different clinical manifestations have also been hypothesized.2–6 Among these, impaired cell metabolism has been suggested as a key pathophysiological process. In particular, defective oxidative metabolism seems to be involved in visceral fat gain and in the development of insulin resistance in fat and skeletal muscle. This suggests that mitochondrial function may be impaired in the metabolic syndrome and, thus, in the linked cardiovascular diseases. Recently, we have reported that mitochondrial biogenesis and function are increased by nitric oxide (NO) in various cell types and tissues, including cardiac muscle.7,8
The purpose of this review is to give a brief overview of NO and mitochondrial biogenesis in relation to cardiac energy metabolism and to suggest new insights into how alterations in this metabolic pathway may lead to the development of cardiovascular disease linked to the metabolic syndrome.
|
The Metabolic Syndrome and Atherosclerotic Vascular Disease |
|---|
In 2001, the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) suggested a clinical definition for the metabolic syndrome that includes blood pressure, waist circumference, high-density lipoprotein (HDL) cholesterol, and triglyceride and fasting plasma glucose levels.3 According to Third National Health and Nutrition Examination Survey (NHANES III) data, the age-adjusted prevalence for the NCEP-defined metabolic syndrome in the US population is 23.7%.9 The high prevalence of the metabolic syndrome has significant public health implications because of the 2-fold increased risk of prevalent coronary heart disease,10 3- to 4-fold increased risk of mortality attributable to coronary heart disease,11 and a 6-fold risk of developing type 2 diabetes mellitus.12
The underlying pathophysiology of the metabolic syndrome is a subject of debate. Initial studies in this area suggested that insulin resistance has a primary role.13–16 However, more recent investigations show that visceral adiposity is a significant independent predictor of the insulin sensitivity,17–21 impaired glucose tolerance,22 elevated blood pressure,23–25 and dyslipidemia19,26–32 seen in the metabolic syndrome. Furthermore, intraabdominal fat is metabolically active as a source of free fatty acids33,34 and adipokines, such as adiponectin,35,36 and of inflammatory mediators such as tumor necrosis factor- (TNF-)34,37,38 and plasminogen activator inhibitor type 1 (PAI-1).39,40
A recent study has examined the relation of insulin sensitivity and intraabdominal adipose tissue and subcutaneous fat areas with the NCEP ATP III criteria for the metabolic syndrome in a nondiabetic population.41 The metabolic syndrome was defined according to the NCEP ATP III as the presence of 3 or more of the following clinical criteria3: blood pressure of 
130/85 mm Hg; waist circumference of >102 cm in men and >88 cm in women; HDL cholesterol of <1.036 mmol/L (40 mg/dL) in men and <1.295 mmol/L (50 mg/dL) in women; triacylglycerol of 1.695 mmol/L (150 mg/dL); and fasting plasma glucose levels 6.1 mmol/L (110 mg/dL).
In this study, performed on a large number of apparently healthy men and women of varying age, the authors showed that both insulin resistance and central adiposity are significant correlates of the metabolic syndrome.3 The intraabdominal fat area was independently associated with all of the metabolic syndrome criteria, whereas insulin sensitivity was independently associated with the criteria for HDL cholesterol, triacylglycerol, and fasting plasma glucose levels. In contrast, the subcutaneous fat area was independently correlated with waist circumference after adjusting for visceral fat area and insulin sensitivity, but not with other metabolic syndrome criteria. The results of this study, therefore, suggest that accumulation of intraabdominal adipose tissue is an important determinant of the metabolic syndrome. Furthermore, the significant association of visceral adiposity with all the features of the metabolic syndrome, including increased risk of cardiovascular disease, was in part independent of the effect of insulin resistance and abdominal subcutaneous fat, suggesting an important role for visceral adiposity.
Visceral adiposity, but not abdominal subcutaneous fat, is independently associated with insulin resistance27; lower HDL cholesterol levels27,28; higher apolipoprotein B28,31 and triglyceride levels27,28; smaller low-density lipoprotein particles28,31; aortic stiffness42; coronary artery calcification43; and higher blood pressure.23–25,32 Furthermore, a reduction in visceral fat by weight loss or surgical removal is associated with increases in insulin sensitivity44,45 and HDL cholesterol46 and decreases in triglycerides46 and blood pressure.24,46 Thus, visceral adiposity, independently from insulin resistance, may have a significant pathophysiological role in the development of the metabolic syndrome and its sequelae. In this context, in 2004, a group of experts was convened by the International Diabetes Federation to attempt to establish a unified definition for the metabolic syndrome and to highlight areas where more research into the syndrome is needed. A major issue for the International Diabetes Federation consensus consultation was the importance of obesity as a risk factor for several diseases including type 2 diabetes mellitus, cardiovascular disease, hypertension, gallstone disease, and certain cancers.6,47 Interestingly, the amount of obesity associated with increased risk differs among populations.48 At present, the ATP III update5 and the International Diabetes Federation report6 largely harmonize the clinical diagnosis of the syndrome. From the above reports, it clearly emerges that the risk for atherosclerotic cardiovascular disease associated with the metabolic syndrome is greater than the sum of its risk factors.1
|
Is There a Defect in Oxidative Metabolism in the Metabolic Syndrome? |
|---|
A recent study in subjects who were nondiabetic, insulin-resistant and at high risk for diabetes ("prediabetes"), or had type 2 diabetes mellitus, has demonstrated that prediabetic and diabetic muscle is characterized by a decreased expression of genes involved in oxidative phosphorylation, many of which are regulated by nuclear respiratory factor (NRF)-dependent transcription.49 Furthermore, in both prediabetic and diabetic subjects, there is a significant reduction in the expression of peroxisome proliferator-activated receptor-
(PPAR-) coactivator 1 (PGC-1), which is an inducible coregulator of nuclear receptors such as NRF involved in the control of mitochondrial biogenesis and functions (Figure 1).50,51 These data indicate that decreased PGC-1 expression may be responsible for the reduced expression of metabolic and mitochondrial genes regulated by NRF and may contribute to the metabolic disturbances characteristic of insulin resistance, diabetes mellitus, and, perhaps, obesity. In contrast, there is evidence to indicate that the expression of genes and gene targets involved in mitochondrial biogenesis and function is increased in the heart in type 1 diabetes.52 Whereas the healthy adult mammalian heart generates ATP via both carbohydrate utilization and mitochondrial fatty acid oxidation pathways, the diabetic heart derives most of its ATP from fatty acid oxidation,53 with an activated cardiac PPAR-/PGC-1 system.54 This metabolic shift may initially be adaptive to maintain the required rate of ATP production. However, uncontrolled high-level fatty acid import and oxidation may eventually become maladaptive, leading to pathological mitochondrial and myocardial remodeling. Indeed, dysfunction has been described in heart mitochondria from insulin-resistant and diabetic animals,52,55 and this is associated with reduced transcriptional activity of the mitochondria.55
|
In both obesity and common forms of type 2 diabetes mellitus, glucose oxidation and storage are reduced, in parallel with reduced activity of the tricarboxylic acid cycle, ß oxidation, and electron transport enzymes, specifically complex I,56,57 with reductions in mitochondrial area and number.57–59 A potential role for dysregulation of oxidative metabolism gene expression in diabetes mellitus is suggested by studies in animals and humans. In streptozotocin-induced diabetic mice, the expression of oxidative phosphorylation genes has been reported to be decreased.60 Similarly, the expression of multiple energy metabolism genes is altered in poorly controlled type 2 diabetes mellitus in humans.61 In both studies, some differences were partly reversed by insulin, suggesting that differential regulation in diabetes may, at least in part, reflect secondary changes, perhaps caused by decreases in NRF-1 expression or transcriptional activity. However, although less pronounced, alterations in oxidative phosphorylation genes were also observed in insulin-resistant nondiabetics. Accordingly, the expression of 2 electron chain subunits (NADH dehydrogenase 1 and ATP5C1) is reduced in insulin-resistant nondiabetic Pima Indians,62 and the expression of ATP synthase subunit F is reduced in the insulin-resistant normoglycemic ob/ob mouse.63 A similar reduction in the expression of oxidative phosphorylation genes has been shown in white subjects with impaired glucose tolerance and type 2 diabetes mellitus.64 These results suggest that the metabolic syndrome is accompanied by a deficit of mitochondrial biogenesis and function.
|
Oxidative Metabolism in Animal Models of the Metabolic Syndrome |
|---|
To identify genes whose expression correlated with body mass index (kilograms per meter squared) and with associated clinical situations, including the metabolic syndrome, a recent study profiled gene expression in perigonadal adipose tissue from mice (the agouti [Ay] and obese [Lepob]) in which adiposity varied because of sex, diet, and the obesity-related mutations.65 This analysis identified 1304 transcripts that were significantly correlated to body mass. Analysis of the 100 transcripts that correlated most closely to body mass revealed 3 groups of functionally related genes that were coordinately regulated. Thirty percent of the 100 most significantly correlated transcripts encoded proteins characteristically expressed by macrophages, such as the macrophage-colony stimulating factor-1 receptor and the CD68 antigen, and 6% encoded lysosomal proteins. Most interestingly, in the context of this review, 12% of transcripts encoded mitochondrial proteins such as succinate dehydrogenase complex, subunit B, iron sulfur, and ubiquinol–cytochrome c reductase subunit. The expression of all of the macrophage and lysosomal transcripts correlated positively with body mass, whereas the expression of each mitochondrial transcript correlated negatively.65 These results strengthen the possibility that mitochondrial biogenesis and functions are defective in visceral fat of patients affected by the metabolic syndrome.
It has been demonstrated that leptin, the deficiency of which is linked either to massive obesity (ob/ob mice) or very marked insulin resistance (lipodystrophy),66,67 induces the expression of the PGC-1 gene in brown adipose tissue (BAT).68 Thus it is likely that mitochondria in adipose tissue is involved in the pathophysiology of the metabolic syndrome (see Figure 1). Although the action of leptin on mitochondrial biogenesis is controversial,69 profound morphological and molecular changes in mitochondria of white fat cells (which store energy in the form of fat) have recently been described in a model of adenovirus-induced hyperleptinemia.70 These include shrinkage, loss of fat, and loss of shape of adipocytes, with extensive infoldings of the cell membrane. The modified cells (postadipocytes) contained a profusion of mitochondria that differed in size and appearance from the much larger mitochondria of brown adipocytes, which are mitochondria-rich cells specialized for thermogenesis. PGC-1 mRNA rose from the very low levels normally present in white adipose tissue (WAT) to those of BAT. PGC-1 is involved in mitochondrial biogenesis; thus its increase might be causally linked with the abundance of mitochondria in postadipocytes. Indeed, when PGC-1 was not increased, as in fat cells of adenovirus-leptin-treated PPAR-null mice, the hyperleptinemia failed to induce adipocyte fat loss.71 Because forced expression of PGC-1 in human fat cells enhances their oxidation of fatty acids,72 it is quite likely that its increase was responsible for the loss of fat through "internal combustion." The abundance of mitochondria, induced by the high PGC-1 levels, would increase the machinery required for enhanced oxidation, whereas increased uncoupling protein-1 and -2, the expression of which is enriched in the thermogenically active BAT, would dissipate the unneeded energy as heat. Although this combination of events was reminiscent of hyperthyroidism, triiodothyronine levels were not increased in the plasma of the leptinized rats.70
|
Endothelial Nitric Oxide Synthase–Null Mice: A Model of the Metabolic Syndrome? |
|---|
Endothelial nitric oxide synthase (eNOS) deficiency in null-mutant mice has been found to be associated with a clustering of cardiovascular risk factors that mirror those present in patients with the metabolic syndrome.7,73 eNOS–/– mice are hypertensive, insulin resistant, and have dyslipidemia.74–76 Furthermore, they have been reported to have elevated plasma levels of leptin, uric acid, and fibrinogen and to become more glucose intolerant than control mice when challenged with a metabolic stress, such as a high-fat diet.73 The augmented leptin plasma levels in eNOS–/– mice suggest that body weight and/or relative adipose tissue content may be raised in the knockout mice, resulting from the fact that fat accumulation increases adipose leptin synthesis and release. We have shown that in eNOS–/– mice, there is a marked accumulation of visceral fat (Figure 2) and body weight is increased.7 We also found that oxygen consumption rates—an indicator of metabolic rate—are decreased in these animals, suggesting that brown fat–dependent thermogenesis is impaired.7 In genetic models of obesity, defective energy expenditure is involved in body weight gain. Because 8-week-old eNOS–/– mice showed similar food consumption but weighed more than wild-type mice, their increased body weight could be accounted for by higher feed efficiency (ie, weight gain/food intake) caused by defective energy expenditure. Indeed, histological analysis indicated that eNOS–/– BAT was functionally inactive, and exposure of these animals to cold did not result in the well-known mitochondriogenic process that is usually observed in wild-type animals. In addition, deletion of eNOS was sufficient to reduce the number and function of mitochondria even in tissues that have a basal level of neuronal, and possibly inducible NOS expression, such as the brain, liver and heart.7 These findings led us to suggest a critical role for eNOS in mitochondrial biogenesis.
|
Our group and others have observed that NO generation is triggered by many of the stimuli initiating BAT differentiation, including cold exposure and physical exercise. Cold exposure triggers eNOS, inducible NOS, and PGC-1 expression,77–79 through activation of ß3-adrenergic receptors and increases in intracellular cAMP and Ca2+, all of which stimulate NO production in brown adipocytes.77 eNOS can be activated through increases in cytosolic Ca2+ concentrations and phosphorylation by various protein kinases, including AMP-activated protein kinase, suggesting that different mitochondriogenic stimuli might act, at least in part, through the generation of NO.
Both in vivo and in vitro evidence has indicated that NO, either exogenously applied or generated by eNOS, plays a significant role in brown adipocyte differentiation, proliferation and thermogenesis78,80–82 Systemic inhibition of NOS with NG-monomethyl-L-arginine caused defective adaptive thermogenesis in rodents.83,84 Interestingly, mitochondrial conversion of 3-[4,5-dimethylthiazol-2-yl-]-2,5-diphenyl tetrazolium bromide (MTT) to formazan, a method usually used for the indirect measurement of cell proliferation on the basis of mitochondrial dehydrogenase activity, was reduced by only 30% to 40% in spite of the complete inhibition of brown fat cell proliferation after chronic treatment with NO donors.76 These results suggest that NO may promote mitochondrial biogenesis in brown fat cells even while inhibiting cell proliferation.
To investigate this issue, we studied the mitochondrial biogenesis in primary cultures of mouse brown and white fat cells and found that treatment with NO donors increased the mitochondrial DNA (mtDNA) content in these cells.7 We also found that NO-stimulated mitochondrial biogenesis occurred through activation of PGC-1 in BAT and cardiac and skeletal muscle. Furthermore, we demonstrated that the mitochondrial biogenesis depends on cGMP. Similar results were obtained in mouse white-fat 3T3-L1 and human monocytic U937 cell lines, revealing that the NO-dependent mitochondrial biogenesis was not restricted to brown adipocytes and their differentiation processes. To investigate the role of endogenous NO, we stably transfected HeLa cells with eNOS and found that its induction was sufficient to initiate mitochondrial biogenesis in the transfected cells.7
Interestingly, key signaling molecules mediating the metabolic actions of insulin, including the insulin receptor tyrosine kinase, phosphatidylinositol 3-kinase, and Akt,85 are also necessary for insulin to stimulate production of NO and vasodilation in human vascular endothelium.86 In particular, insulin induces eNOS phosphorylation at Ser1179 through activation of Akt with an increased production of NO.87 Thus, one physiological role of the eNOS-derived NO in vascular endothelium may be to mediate the action of insulin in coupling hemodynamic and metabolic homeostasis.
eNOS is known to be present in murine myocardium, not only in the microvascular and arterial endothelium88 but also in the cardiac myocytes.89 Studies in eNOS–/– mice subjected to myocardial infarction have demonstrated the role of eNOS in limiting left ventricular dilatation, dysfunction, and hypertrophy, possibly by limiting the hypertrophic response to myocardial infarction.90 The eNOS deficiency was associated with increased mortality after myocardial infarction.90
|
Mitochondrial Biogenesis Is Impaired in Obesity |
|---|
Obese subjects are deficient in energy in the form of ATP.91,92 Inadequate energy supply in the body results in increased appetite. Although the mechanism of such signaling is not yet known, there is evidence that it exists.93–95 Treatment of rats with the metabolic inhibitors 2,5-anhydro-d-mannitol or/and methyl palmoxirate reduces the ATP levels in liver cells. Decreasing ATP concentrations in this way has been shown to lead to changes in the eating habits of the animals, including the frequency of eating, the amount of food consumed at a single eating session, and the total amount of food eaten. These experiments indicate that there is an integrated metabolic control of food intake, with liver ATP levels acting as a major sensor of energy status in the body. In obese people, the levels of hepatic ATP are decreased. Moreover, a decreased exercise capacity, together with high fatigability, has been linked to the low ATP levels in skeletal muscle of obese subjects.96 In this context, genetically heterogeneous rats can be separated into 2 groups according to their aerobic treadmill-running capacity, with low-capacity runners showing higher visceral adiposity, blood pressure, insulin-resistance, plasma triglycerides, and free fatty acids as compared with the high-capacity runners.97 Intriguingly, mitochondrial dysfunction with a defective oxidative metabolism and a low mitochondrial gene expression were evident in low-capacity runners,97 suggesting that visceral obesity and related disorders are linked to defective mitochondrial biogenesis and oxidative metabolism with a decreased ATP production. Recent studies in obese rodents have supported this hypothesis, not only at the molecular and biochemical but also at the morphological level.98,99 In our experiments in 3 models of obesity, we found that eNOS expression was markedly reduced in WAT, BAT, and soleus muscle of ob/ob mice, fa/fa rats, and high-fat diet–induced obese mice (DIO mice).100 Moreover, mtDNA, respiratory protein (such as COX IV and Cyt c) levels, PGC-1
, NRF-1, and mtDNA transcription factor A (Tfam) gene expression were decreased in parallel, as well as oxygen consumption and ATP production.100 Changes in mitochondrial morphology were also observed in tissues from obese animals; these paralleled the functional deficits of mitochondria, suggesting an increase of the fission events in mitochondrial dynamics. The possibility that altered mitochondrial dynamics plays a role in the pathophysiology of mitochondrial dysfunction linked to obesity is supported by the observation that the expression of mitofusin 2, which is involved in the mitochondrial fusion events, was reduced in skeletal muscle of both eNOS–/– mice (E.N. and C. Tonello, unpublished results, 2006) and obese fa/fa rats.101 As mentioned above, large-scale gene-expression analyses in obese animals65,102,103 and humans49,64 have demonstrated that many genes encoding mitochondrial proteins are negatively correlated with body mass,104 providing further evidence that mitochondrial dysfunction is significant in the pathophysiology of obesity. Additionally, mice with genetic deletion of NEIL1 DNA glycosylate, an enzyme involved in base excision repair of ring-fragmented purines and some pyrimidines, have increased mtDNA damage and deletions and develop severe obesity with dyslipidemia, fatty liver disease, and a tendency toward hyperinsulinemia.105
Consistent with our observations in the metabolically active tissues of obese rodents, a 3.7-fold decrease of eNOS expression in total abdominal WAT of male DIO mice and an inverse correlation between the skeletal muscle eNOS content and the percentage body fat and body mass index in young adult women have been described.106,107 In this context, dietary supplementation with L-arginine, which increases serum NO concentration and PGC-1 expression in WAT, has been shown to reduce fat mass in Zucker Diabetic Fatty (ZDF) rats 4 to 10 weeks after the initiation of treatment.108
|
Inflammation and Obesity |
|---|
The proinflammatory cytokine TNF-
is overproduced in the adipose as well as muscle tissues of obese subjects.65,103,109,110 We have shown that TNF- markedly decreased both eNOS expression and mitochondrial biogenesis in cultured fat and muscle cells. Downregulation of eNOS seems to be the major molecular mechanism by which TNF- affects mitochondrial biogenesis in in vitro models, because its effects on mitochondria can be reversed by treatment with the NO donors (Z)-1-[N-(2-aminoethyl)-N-(2-aminoethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO) and S-nitroso-N-acetylpenicillamine (SNAP).100 Furthermore, mitochondrial biogenesis in WAT, BAT, and muscle was at least partially restored in obese mice with defective TNF- signaling (ie, obese mice with genetic deletion of TNF- receptors, either p55 or p75 or both). This partial recovery of mitochondrial biogenesis in WAT and BAT of both ob/ob p55–/– and ob/ob p55–/–p75–/– mice was accompanied by a full restoration of eNOS expression in these tissues.100 These results suggest that TNF- plays a relevant role in decreasing eNOS expression and mitochondrial biogenesis in metabolically active tissues of obese animals. The fact that ob/ob p55–/–p75–/– mice behaved similarly to the ob/ob p55–/– mice in terms of mitochondrial parameters suggests that p55 is the most relevant receptor in mediating the effects of TNF-.
In different animal models of obesity, it has been shown that the production of TNF- is increased in adipose tissue and that it induces insulin resistance.109 Other active substances were subsequently found to be produced in fat; these include leptin, interleukin (IL)-6, resistin, monocyte chemoattractant protein-1, PAI-1, angiotensinogen, visfatin, retinol-binding protein-4, serum amyloid A.111–114 Whereas leptin and adiponectin are true adipokines that appear to be produced exclusively by adipocytes, TNF-, IL-6, monocyte chemoattractant protein-1, visfatin, and PAI-1 are also expressed at high levels in activated macrophages and/or other cells. Thus, obesity has emerged over the last few years as a chronic, low-grade inflammation. This inflammatory state is evident in adipose tissue, liver, and skeletal muscle. Inflammation is also closely linked to the pathogenesis of atherosclerosis, suggesting that inflammation might be a common factor that links obesity to many of its pathological sequelae. Indeed, increasing evidence indicates the existence of a link among mitochondrial dysfunction, increased TNF- serum levels, and cardiovascular disease.115–118 This evidence, together with that described in the following section, strongly suggests that defects in mitochondrial number and/or function are causally linked to the cardiovascular alterations found in obesity and the metabolic syndrome.
Potential mechanisms for activation of inflammation in adipose tissue are intensely investigated and can be summarized as follows. Nutrients such as lipids and cytokines such as TNF- and IL-1ß can trigger inflammatory kinases, including c-Jun N-terminal kinase (JNK) and I
B kinase/nuclear factor B (IKKß/NF-B) (Figure 3) through classical receptor-mediated mechanisms that have been well characterized. These kinases have been reported to exert powerful effects on gene expression, including promoting further expression of inflammatory genes through activation of activator protein-1 complexes. NF-B119 and JNK2 activity has also been implicated in the pathogenesis of atherosclerosis.120 Cellular stresses, including reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress, also activate JNK and IKK, both of which then regulate the production of various cytokines, including TNF-. ROS has been implicated in the development of obesity-induced insulin resistance because systemic markers of oxidative stress increase with adiposity.121 Furthermore, under pathophysiological conditions, such as inflammation, hyperglycemia, hyperlipidemia, and hypoxia, all of which are present in obesity, ROS and NO may react avidly. Consequently, the half-life of the bioactive NO is reduced and reactive nitrogen species, particularly dinitrogen trioxide and peroxynitrite (ONOO–), are generated with significant damage to cellular components up to cell death.122 Lipid accumulation also activates the unfolded protein response to increase ER stress in fat and liver.123 Hyperactivation of JNK by ER stress has been reported to result in serine phosphorylation of insulin receptor substrate-1. Furthermore, ER stress has been shown to activate NF-B. These observations suggest that obesity may be a chronic stimulus for ER stress, which itself may be a central mechanism underlying peripheral insulin resistance.123 Once activated, the processes may be self-perpetuating through a positive-feedback loop created by the proinflammatory cytokines produced (Figure 3).
|
These findings suggest that the inadequate utilization of body energy100,124,125 conveys to the brain of obese subjects an "emergency" signal difficult to ignore, namely that "more energy is needed to survive."126 As a consequence, obese subjects increase their food intake and restrict physical activity to maintain energy supply to the body.91 Thus, although overeating and a sedentary lifestyle lead to fat accumulation, they might not be the only pathophysiological bases of obesity. In fact, they may be the result of an already "obese metabolism," which would force individuals to overeat and preserve energy.91 This hypothesis may be supported by the observation that, whereas, in normal-weight animals, a moderate calorie restriction enhances mitochondrial oxidative capacity127 by increasing eNOS expression and mitochondrial biogenesis128; in obese subjects, a restrictive diet lowers further an already defective lipid oxidation in different tissues,129 probably because of the lack of the compensatory NO-related mitochondrial biogenesis.100 These findings suggest that a decrease in inflammatory processes and increase in mitochondrial mass in metabolically active tissues might provide a way of managing obesity and related disorders, including insulin resistance, type 2 diabetes mellitus, and some forms of cardiovascular disease.
|
Are There Pathophysiological Consequences of Defective NO-Induced Mitochondrial Biogenesis in the Heart of Obese Subjects? |
|---|
Although there are clinical reports of cardiomyopathy of obesity that can be reversed by weight loss,130 cardiac dysfunction, arrhythmias, cardiomyopathy, and congestive heart failure are at present attributed by most clinicians to atherosclerotic consequences of obesity, including coronary artery disease and hypertension.131 Nevertheless, increasing evidence indicates that lipotoxic heart disease exists both alone and in concert with these well-recognized causes of heart disease and that it impairs the ability of the myocardium to compensate for them.54,132–134 However, the details of the mechanism involved require further investigation because, in fact, nonadipocytes have a very limited capacity to store excess fat.135 If they are exposed to high levels of plasma lipids, as usually occurs in obesity, they may undergo steatosis and loss of function, and ultimately fatty acid–induced "lipoapoptosis" may occur.135 In ZDF fa/fa rats, a model of obesity secondary to genetic unresponsiveness to leptin, as the animals become increasingly obese, triacylglycerol accumulates rapidly in the heart and in other nonadipose tissues.136 This is the consequence not only of elevated plasma lipids but also of increased expression in nonadipose tissues of lipogenic enzymes such as glycerol-phosphate acyltransferase coupled with decreased expression of acyl-CoA oxidase and carnitine palmitoyltransferase-1 and their transcription factor, PPAR-
. These changes are associated with a progressive increase in ceramide content and increased apoptosis, resulting in myocyte dysfunction or death, termed "lipotoxicity." Significant reduction in fractional area shortening is observed at 20 weeks of age of ZDF fa/fa rats, indicating a clinically significant reduction in cardiac contraction.136 As previously noted, some other studies have shown that the insulin-resistant and diabetic heart exhibit a markedly increased capacity for fatty acid oxidation, associated with an activation of PPAR- and its target genes involved in this process at least in the short term.54 Thus, one can suggest that in the ZDF fa/fa rat the expression of PPAR- and its target genes begins to fall in the latter stages of disease. A further pathophysiological mechanism of cardiomyopathy in obesity may originate from defects in eNOS-dependent signaling, because eNOS expression is decreased in the heart of obese rodents (our unpublished results). Indeed, the accumulation of triacylglycerol and consequent reduction in cardiac contraction may also be attributable to a reduced ß-oxidation of fatty acids in cardiomyocytes resulting from impaired mitochondrial biogenesis and function. Evidence for a link between mitochondrial respiratory dysfunction and heart failure is compelling. The cardiomyopathic phenotype of humans with mitochondrial genome defects underscores the importance of high-capacity mitochondrial ATP production for normal striated-muscle function. Mutations in both nuclear- and mitochondrial-encoded genes account for heritable respiratory chain defects.137,138 Respiratory chain defects typically present as a multisystem dysfunction, disproportionately affecting organs with a high demand for ATP, such as the heart, skeletal muscle, and the central nervous system. Cardiomyopathy may develop during childhood or at later ages.
Several recently developed mouse models have identified potential links between PGC-1–mediated control of mitochondrial function and the development of heart failure. PGC-1 is abundantly expressed in the heart. As seen previously, PGC-1 activates most genes of mitochondrial function and biogenesis and stimulates both fatty acid oxidation and oxidative respiration in cardiac tissue.139–141 Conversely, it has recently been shown that ablation of the PGC-1 gene caused significant deficiencies in cardiac energy reserves and function.142 In the absence of PGC-1, the expression of mitochondrial genes in the heart was suppressed, the activities of mitochondrial enzymes were aberrant, and ATP production was blunted. These energetic defects led to an inability to increase contractile function when the hearts were stimulated with adrenergic agents. Mice lacking the PGC-1 transcriptional coactivator develop cardiac dysfunction in response to cardiac duress initiated by constriction of the transverse thoracic aorta, a commonly used model of pressure overload in rodents and other animals.143 The cardiac dysfunction observed was accompanied by clinical signs of heart failure.
Overexpression of cyclin T/Cdk9, an RNA polymerase kinase, has recently been shown to trigger cardiac hypertrophy.144 Gene expression–profiling studies demonstrated that Cdk9 suppresses the expression of PGC-1 and its downstream targets. Rescue of PGC-1 expression in cardiac myocytes in culture prevented Cdk9-triggered apoptosis. Despite strong evidence for a link between mitochondrial dysfunction and heart failure in genetic models, the role of altered mitochondrial ATP generation in the pathogenesis of acquired forms of heart failure still requires investigation.
Finally, mature human adipocytes have been reported to release a substance that strongly and acutely suppresses the contraction of electrically paced adult cardiomyocytes by reducing intracellular Ca2+. This adipocyte-derived negative inotropic activity appeared to be a protein with a molecular mass between 10 and 30 kDa.145 These findings suggest a direct involvement of adipose tissue in the pathogenesis of myocardium dysfunction.
The evidence summarized above indicates that defects of the NO-induced mitochondrial biogenesis, with decreased PGC-1 expression, are relevant in the pathophysiology of cardiovascular disease linked to obesity. Further support for this concept comes from the fact that eNOS-dependent synthesis of NO by the vascular endothelium regulates arterial pressure74,146,147 and is defective in human essential hypertension.148 Endothelium-derived NO also mediates insulin-induced stimulation of the perfusion of skeletal muscle.149 In insulin-resistant individuals, insulin stimulation of endothelial NO production is impaired and may contribute to defective skeletal muscle glucose uptake.150 In line with this, NOS inhibitors reduce insulin-stimulated muscle glucose uptake in rats in vivo.151 Furthermore, eNOS is expressed in the skeletal muscle,152 and NO donors stimulate glucose transport in isolated rat muscle preparations.153–155
Partial gene deletion of eNOS (eNOS+/– mice) has been shown to predispose to exaggerated high-fat diet–induced insulin resistance and arterial hypertension, suggesting an important interaction between genetic (eNOS polymorphism) and environmental factors (high-fat diet) in the regulation of vascular NO synthesis and glucose and blood pressure homeostasis.156 Thus, the development of the metabolic syndrome and cardiovascular disease might be facilitated by the combination of a genetic predisposition (eg, eNOS polymorphisms) together with environmental factors such as a Western-type diet.
The relationship among eNOS deficiency, mitochondrial biogenesis, and cardiovascular disease linked to the metabolic syndrome has been demonstrated in rodents. Whether these findings are applicable to humans is still unknown. However, there is some evidence that hypertension, coronary artery disease, and myocardial infarction might be associated with eNOS gene polymorphism.157–162 The resultant impaired NO synthesis160,161 could predispose to insulin resistance and the metabolic syndrome.163–165
At present, most clinicians attribute the cardiac defects that occur in obesity to coronary artery disease or hypertension, because these are established diagnostic categories commonly associated with obesity. The evidence reported in this review, however, suggests that lipotoxic heart disease, characterized by defective mitochondrial biogenesis and increased apoptosis, can act both alone and in concert with these well-recognized causes of heart disease, possibly by impairing the ability of the myocardium to compensate for them.
|
Conclusions |
|---|
In summary, evidence is emerging to support the concept that alterations in mitochondrial biogenesis and energetics of cardiomyocytes are linked to the development and progression of cardiovascular disease and heart failure in obesity. Accordingly, signaling pathways involved in cardiac ATP generation, including eNOS-dependent NO production and PGC-1
–modulated expression of genes involved in mtDNA replication and cell respiration, are attractive targets to consider as potential novel therapeutic strategies for the prevention and early treatment of obesity-linked heart diseases.
|
Acknowledgments |
|---|
We thank A. Higgs for help with manuscript preparation.
Sources of Funding
This work was supported by grants from the Ministero dell’Istruzione, dell’Università e della Ricerca cofinanziamento 2005, the University of Milan and the Italian Ministry of Health (to E.N.); and the Medical Research Council (to S.M.).
Disclosures
None.
|
Footnotes |
|---|
Original received November 2, 2006; revision received December 21, 1006; accepted January 24, 2007.
|
References |
|---|
1. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47: 1093–1100.
2. Federspil G, Nisoli E, Vettor R. A critical reflection on the definition of metabolic syndrome. Pharmacol Res. 2006; 53: 449–456.[CrossRef][Medline] [Order article via Infotrieve]
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; Am Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome. An Am Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735–2752.
6. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005; 366: 1059–1062.[CrossRef][Medline] [Order article via Infotrieve]
7. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003; 299: 866–899.
8. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, Clementi E. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A. 2004; 101: 16507–16512.
9. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356–359.
10. Alexander C, Landsman P, Teutsch S, Haffner S. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52: 1210–1214.
11. Lakka H-M, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E, Tuomilehto J, Salonen J. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288: 2709–2716.
12. Laaksonen D, Lakka H-M, Niskanen L, Kaplan G, Salonen J, Lakka T. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002; 156: 1070–1077.
13. Ferrannini E, Haffner S, Mitchell B, Stern M. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; 34: 416–422.[CrossRef][Medline] [Order article via Infotrieve]
14. Ferrannini E, Buzzigoli G, Bonadonna R. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317: 350–357.[Abstract]
15. Reaven G. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993; 44: 121–131.[CrossRef][Medline] [Order article via Infotrieve]
16. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1495–1607.
17. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996; 45: 633–638.[Abstract]
18. Cnop M, Landchild M, Vidal J, Havel P, Knowles N, Carr D, Wang F, Hull R, Boyko E, Retzlaff B, Walden C, Knopp R, Kahn S. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes. 2002; 51: 1005–1015.
19. Katsuki A, Sumida Y, Urakawa H, Gabazza E, Murashima S, Maruyama N, Morioka K, Nakatani K, Yano Y, Adachi Y. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese, metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care. 2003; 26: 2341–2344.
20. Wagenknecht L, Langefeld C, Scherzinger A, Norris J, Haffner S, Saad M, Bergman R. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003; 52: 2490–2496.
21. Fujimoto W, Abbate S, Kahn S, Hokanson J, Brunzell J. The visceral adiposity syndrome in Japanese-Am men. Obes Res. 1994; 2: 364–371.[Medline] [Order article via Infotrieve]
22. Hayashi T, Boyko E, Leonetti D, McNeely M, Newell-Morris L, Kahn S, Fujimoto W. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care. 2003; 26: 650–655.
23. Rattarasarn C, Leelawattana R, Soonthornpun S, Setasuban W, Thamprasit A, Lim A, Chayanunnukul W, Thamkumpee N, Daendumrongsub T. Regional abdominal fat distribution in lean and obese Thai type 2 diabetic women: relationships with insulin sensitivity and cardiovascular risk factors. Metabolism. 2003; 52: 1444–1447.[CrossRef][Medline] [Order article via Infotrieve]
24. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Kameda-Takemura K, Matsuzawa Y. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension. 1996; 27: 125–129.
25. Bacha F, Saad R, Gungor N, Janosky J, Arslanian S. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab. 2003; 88: 2534–2540.
26. Carr M, Hokanson J, Deeb S, Purnell J, Mitchell E, Brunzell J. A hepatic lipase gene promotor polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. Arterioscler Thromb Vasc Biol. 1999; 19: 2701–2707.
27. Ribeiro-Filho F, Faria A, Kohlmann N, Zanella M-T, Ferreira S. Two-hour insulin determination improves the ability of abdominal fat measurement to identify risk for the metabolic syndrome. Diabetes Care. 2003; 26: 1725–1730.
28. Pascot A, Despres JP, Lemieux I, Bergeron J, Nadeau A, Prud’homme D, Tremblay A, Lemieux S. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia. 2000; 43: 1126–1135.[CrossRef][Medline] [Order article via Infotrieve]
29. Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Despres JP. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res. 2001; 42: 2007–2014.
30. Nicklas B, Penninx B, Ryan A, Berman D, Lynch N, Dennis K. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 2003; 26: 1413–1420.
31. Nieves D, Cnop M, Retzlaff B, Walden C, Brunzell J, Knopp R, Kahn S. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003; 52: 172–179.
32. Phillips G, Jing T, Heymsfield S. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism. 2003; 52: 784–790.[CrossRef][Medline] [Order article via Infotrieve]
33. Lonnqvist F, Thome A, Nilsell K, Hoffstedt J, Arner P. A pathogenic role of visceral fat beta 3-adrenoreceptors in obesity. J Clin Invest. 1995; 95: 1109–1116.[Medline] [Order article via Infotrieve]
34. van Harmelen V, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, Arner P. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes. 2002; 51: 2029–2036.
35. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 2003; 52: 1274–1278.[CrossRef][Medline] [Order article via Infotrieve]
36. Cnop M, Havel P, Utzschneider K, Carr D, Sinha M, Boyko E, Retzlaff B, Knopp R, Brunzell J, Kahn S. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46: 459–469.[Medline] [Order article via Infotrieve]
37. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998; 83: 859–862.
38. Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger M. Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes Metab. 2000; 26: 178–182.[Medline] [Order article via Infotrieve]
39. Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997; 46: 860–867.[Abstract]
40. Giltay EJ, Elbers JM, Gooren LJ, Emeis JJ, Kooistra T, Asscheman H, Stehouwer CD. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol. 1998; 18: 1716–1722.
41. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004; 53: 2087–2094.
42. Sutton-Tyrrell K, Newman A, Simonsick E, Havlik R, Pahor M, Lakatta E, Spurgeon H, Vaitkevicius P. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension. 2001; 38: 429–433.
43. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001; 21: 2051–2058.
44. Gabriely I, Ma X, Yang X, Atzmon G, Rajala M, Berg A, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002; 51: 2951–2958.
45. Barzilai N, She L, Liu B-Q, Vuguin P, Cohen P, Wang J, Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999; 48: 94–98.[Abstract]
46. Brochu M, Tchernof A, Turner A, Ades P, Poehlman E. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism. 2003; 52: 599–604.[CrossRef][Medline] [Order article via Infotrieve]
47. Eckel RH. Obesity: Mechanisms and Clinical Management. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003.
48. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415–1428.[CrossRef][Medline] [Order article via Infotrieve]
49. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003; 100: 8466–8471.
50. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004; 18: 357–368.
51. Handschin C, Spiegelman BM. PGC-1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006; 27: 728–735.
52. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM Jr, Klein JB, Epstein PN. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab. 2004; 287: E896–E905.
53. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000; 279: E1104–E1113.
54. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPAR overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109: 121–130.[CrossRef][Medline]
[Order article via Infotrieve]
55. Nishio Y, Kanazawa A, Nagai Y, Inagaki H, Kashiwagi A. Regulation and role of the mitochondrial transcription factor in the diabetic rat heart. Ann N Y Acad Sci. 2004; 1011: 78–85.[CrossRef][Medline] [Order article via Infotrieve]
56. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J. 1999; 13: 2051–2060.
57. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002; 51: 2944–2950.
58. Song J, Oh JY, Sung YA, Pak YK, Park KS, Lee HK. Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients. Diabetes Care. 2001; 24: 865–869.
59. Antonetti DA, Reynet C, Kahn CR. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. J Clin Invest. 1995; 95: 1383–1388.[Medline] [Order article via Infotrieve]
60. Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci U S A. 2002; 99: 10587–10592.
61. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes. 2002; 51: 1913–1920.
62. Yang X, Pratley RE, Tokraks S, Bogardus C, Permana PA. Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. Diabetologia. 2002; 45: 1584–1593.[CrossRef][Medline] [Order article via Infotrieve]
63. Vicent D, Piper M, Gammeltoft S, Maratos-Flier E, Kahn CR. Alterations in skeletal muscle gene expression of ob/ob mice by mRNA differential display. Diabetes. 1998; 47: 1451–1458.
64. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34: 267–273.[CrossRef][Medline]
[Order article via Infotrieve]
65. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796–1808.[CrossRef][Medline] [Order article via Infotrieve]
66. Friedman JM. Modern science versus the stigma of obesity. Nat Med. 2004; 10: 563–569.[CrossRef][Medline] [Order article via Infotrieve]
67. Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Socci ND, Friedman JM. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest. 2004; 113: 414–424.[CrossRef][Medline] [Order article via Infotrieve]
68. Kakuma T, Wang ZW, Pan W, Unger RH, Zhou YT. Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression. Endocrinology. 2000; 141: 4576–4582.
69. Gomez-Ambrosi J, Fruhbeck G, Martinez JA. Rapid in vivo PGC-1 mRNA upregulation in brown adipose tissue of Wistar rats by a beta(3)-adrenergic agonist and lack of effect of leptin. Mol Cell Endocrinol. 2001; 176: 85–90.[CrossRef][Medline] [Order article via Infotrieve]
70. Orci L, Cook WS, Ravazzola M, Wang MY, Park BH, Montesano R, Unger RH. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci U S A. 2004; 101: 2058–2063.
71. Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH. PPAR is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A. 2002; 99: 11848–11853.
72. Tiraby S, Tavernier G, Lefort C, Larrcuy D, Bouillaud F, Ricquier D, Langin D. Acquirement of brown fat cell features by human white adipocytes. J Biol Chem. 2003; 278: 33370–33376.
73. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, Thorens B, Scherrer U. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003; 133: 360–363.[Medline] [Order article via Infotrieve]
74. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995; 377: 239–242.[CrossRef][Medline] [Order article via Infotrieve]
75. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes. 2000; 49: 684–687.[Abstract]
76. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104: 342–345.
77. Nisoli E, Tonello C, Briscini L, Carruba MO. Inducible nitric oxide synthase in rat brown adipocytes: implications for blood flow to brown adipose tissue. Endocrinology. 1997; 138: 676–682.
78. Giordano A, Tonello C, Bulbarelli A, Cozzi V, Cinti S, Carruba MO, Nisoli E. Evidence for a functional nitric oxide synthase system in brown adipocyte nucleus. FEBS Lett. 2002; 514: 135–140.[CrossRef][Medline] [Order article via Infotrieve]
79. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998; 92: 829–839.[CrossRef][Medline] [Order article via Infotrieve]
80. Nisoli E, Clementi E, Tonello C, Sciorati C, Briscini L, Carruba MO. Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br J Pharmacol. 1998; 125: 888–894.[CrossRef][Medline] [Order article via Infotrieve]
81. Saha SK, Kuroshima A. Nitric oxide and thermogenic function of brown adipose tissue in rats. Jpn J Physiol. 2000; 50: 337–342.[CrossRef][Medline] [Order article via Infotrieve]
82. Kikuchi-Utsumi K, Gao B, Ohinata H, Hashimoto M, Yamamoto N, Kuroshima A. Enhanced gene expression of endothelial nitric oxide synthase in brown adipose tissue during cold exposure. Am J Physiol Regul Integr Comp Physiol. 2002; 282: R623–R626.
83. Uchida Y, Tsukahara F, Irie K, Nomoto T, Muraki T. Possible involvement of L-arginine-nitric oxide pathway in modulating regional blood flow to brown adipose tissue of rats. Naunyn Schmiedebergs Arch Pharmacol. 1994; 349: 188–193.[Medline] [Order article via Infotrieve]
84. Nagashima T, Ohinata H, Kuroshima A. Involvement of nitric oxide in noradrenaline-induced increase in blood flow through brown adipose tissue. Life Sci. 1994; 54: 17–25.[CrossRef][Medline] [Order article via Infotrieve]
85. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101: 1539–1545.
86. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996; 98: 894–898.[Medline] [Order article via Infotrieve]
87. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem. 2001; 276: 30392–30398.
88. Gyurko R, Kuhlencordt P, Fishman MC, Huang PL. Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J Physiol Heart Circ Physiol. 2000; 278: H971–H981.
89. Ortiz PA, Garvin JL. Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol. 2003; 284: R628–R638.
90. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001; 104: 1286–1291.
91. Wlodek D, Gonzales M. Decreased energy levels can cause and sustain obesity. J Theor Biol. 2003; 225: 33–44.[CrossRef][Medline] [Order article via Infotrieve]
92. Lennmarken C, Sandstedt S, von Schenck H, Larsson J. Skeletal muscle function and metabolism in obese women. J Parenter Enteral Nutr. 1986; 10: 583–587.
93. Koch JE, Ji H, Osbakken MD, Friedman MI. Temporal relationships between eating behavior and liver adenine nucleotides in rats treated with 2,5-AM. Am J Physiol Regul Integr Comp Physiol. 1998; 274: R610–R617.
94. Friedman MI, Harris RB, Ji H, Ramirez I, Tordoff MG. Fatty acid oxidation affects food intake by altering hepatic energy status. Am J Physiol Regul Integr Comp Physiol. 1999; 276: R1046–R1053.
95. Ji H, Graczyk-Milbrandt G, Friedman MI. Metabolic inhibitors synergistically decrease hepatic energy status and increase food intake. Am J Physiol Regul Integr Comp Physiol. 2000; 278: R1579–R1582.
96. Green HJ. Mechanisms of muscle fatigue in intense exercise. J Sports Sci. 1997; 15: 247–256.[CrossRef][Medline] [Order article via Infotrieve]
97. Wisloff U, Najjar SM, Ellingsen O, Haram PM, Swoap S, Al-Share Q. Fernstrom M, Rezaei K, Lee SJ, Koch LG, Britton SL. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science. 2005; 307: 418–420.
98. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005; 54: 8–14.
99. Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS, Yoon YS, Yoon G, Choi KM, Ko YG. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia. 2006; 49: 784–791.[CrossRef][Medline] [Order article via Infotrieve]
100. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L, Cantoni O, Clementi E, Moncada S, Carruba MO, Nisoli E. TNF- downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006; 116: 2791–2798.[CrossRef][Medline]
[Order article via Infotrieve]
101. Rabasa-Lhoret R, Wallberg-Henriksson H, Laville M, Palacin M, Vidal H, Rivera F, Brand M, Zorzano A. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003; 278: 17190–17197.
102. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA, Smith SR. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes. 2005; 54: 1926–1933.
103. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821–1830.[CrossRef][Medline] [Order article via Infotrieve]
104. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest. 2004; 114: 1281–1289.[CrossRef][Medline] [Order article via Infotrieve]
105. Vartanian V, Lowell B, Minko IG, Wood TG, Ceci JD, George S, Ballinger SW, Corless CL, McCullough AK, Lloyd RS. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci U S A. 2006; 103: 1864–1869.
106. Moraes RC, Blondet A, Birkenkamp-Demtroeder K, Tirard J, Orntoft TF, Gertler A, Durand P, Naville D, Begeot M. Study of the alteration of gene expression in adipose tissue of diet-induced obese mice by microarray and reverse transcription-polymerase chain reaction analyses. Endocrinology. 2003; 144: 4773–4782.
107. Hickner RC, Kemeny G, Stallings HW, Manning SM, McIver KL. Relationship between body composition and skeletal muscle eNOS. Int J Obes Relat Metab Disord. 2006; 30: 308–312.[CrossRef][Medline] [Order article via Infotrieve]
108. Fu WJ, Haynes TE, Kohli R, Hu J, Shi W, Spencer TE, Carroll RJ, Meininger CJ, Wu G. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr. 2005; 135: 714–721.
109. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87–91.
110. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. J Clin Invest. 1995; 95: 2409–2415.[Medline]
[Order article via Infotrieve]
111. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83: 847–850.
112. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307–312.[CrossRef][Medline] [Order article via Infotrieve]
113. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2: 800–803.[CrossRef][Medline] [Order article via Infotrieve]
114. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307: 426–430.
115. Marin-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res. 2001; 52: 103–110.[CrossRef][Medline] [Order article via Infotrieve]
116. Li YY, Chen D, Watkins SC, Feldman AM. Mitochondrial abnormalities in tumor necrosis factor-–induced heart failure are associated with impaired DNA repair activity. Circulation. 2001; 104: 2492–2497.
117. Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF- inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004; 287: H1813–H1820.
118. Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L, Bagby GJ, Chilian WM. TNF- contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2006; 26: 475–480.
119. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001; 11: 372–377.[CrossRef][Medline] [Order article via Infotrieve]
120. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, Hersberger M, Eriksson U, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ, Freeman MW, Wagner EF, Matter CM, Luscher TF. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science. 2004; 306: 1558–1561.
121. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003; 23: 434–439.
122. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003; 4: 53–60.[Medline] [Order article via Infotrieve]
123. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457–461.
124. Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005; 112: 2686–2695.
125. Nair SP, Chacko V, Arnold C, Diehl AM. Hepatic ATP reserve and efficiency of replenishing: comparison between obese and nonobese normal individuals. Am J Gastroenterol. 2003; 98: 466–470.[Medline] [Order article via Infotrieve]
126. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Clinical endocrinology and metabolism. Regulation of energy homeostasis by peripheral signals. Best Pract Res Clin Endocrinol Metab. 2004; 18: 497–515.[CrossRef][Medline] [Order article via Infotrieve]
127. Selman C, Phillips T, Staib JL, Duncan JS, Leeuwenburgh C, Speakman JR. Energy expenditure of calorically restricted rats is higher than predicted from their altered body composition. Mech Ageing Dev. 2005; 126: 783–793.[CrossRef][Medline] [Order article via Infotrieve]
128. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005; 310: 314–317.
129. Kempen KP, Saris WH, Kuipers H, Glatz JF, Van Der Vusse GJ. Skeletal muscle metabolic characteristics before and after energy restriction in human obesity: fibre type, enzymatic beta-oxidative capacity and fatty acid-binding protein content. Eur J Clin Invest. 1998; 28: 1030–1037.[CrossRef][Medline] [Order article via Infotrieve]
130. Alpert MA, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM, Panayiotou H, Mukerji V. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997; 80: 736–740.[CrossRef][Medline] [Order article via Infotrieve]
131. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men—morbidity, risk factors and prognosis. J Intern Med. 2001; 249: 253–261.[CrossRef][Medline] [Order article via Infotrieve]
132. Borradaile NM, Schaffer JE. Lipotoxicity in the heart. Curr Hypertens Rep. 2005; 7: 412–417.[Medline] [Order article via Infotrieve]
133. Pillutla P, Hwang YC, Augustus A, Yokoyama M, Yagyu H, Johnston TP, Kaneko M, Ramasamy R, Goldberg IJ. Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy. Am J Physiol Endocrinol Metab. 2005; 288: E1229–E1235.
134. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004; 18: 1692–1700.
135. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999; 96: 2327–2332.
136. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000; 97: 1784–1789.
137. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol. 2000; 88: 2219–2226.
138. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther. 2001; 299: 818–824.
139. Huss JM, Kopp RP, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1 (PGC-1) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor- and -. Identification of novel leucine-rich interaction motif within PGC-1. J Biol Chem. 2002; 277: 40265–40274.
140. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000; 106: 847–856.[Medline]
[Order article via Infotrieve]
141. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor coactivator-1 promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004; 94: 525–533.
142. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM. Transcriptional coactivator PGC-1 controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005; 1: 259–271.[CrossRef][Medline]
[Order article via Infotrieve]
143. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR- coactivator 1. Proc Natl Acad Sci U S A. 2006; 103: 10086–10091.
144. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, Taffet GE, Hamamori Y, Michael LH, Craigen WJ, Schneider MD. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J. 2004; 23: 3559–3569.[CrossRef][Medline] [Order article via Infotrieve]
145. Lamounier-Zepter V, Ehrhart-Bornstein M, Karczewski P, Haase H, Bornstein SR, Morano I. Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity. FASEB J. 2006; 20: 1653–1659.
146. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996; 93: 13176–13181.
147. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989; 86: 3375–3378.
148. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet. 1997; 349: 837–842.[CrossRef][Medline] [Order article via Infotrieve]
149. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest. 1994; 94: 2511–2515.[Medline] [Order article via Infotrieve]
150. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97: 2601–2610.[Medline] [Order article via Infotrieve]
151. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol Endocrinol Metab. 1998; 274: E692–E699.
152. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes. 1997; 46: 1691–1700.[Abstract]
153. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes. 2001; 50: 241–247.
154. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol. 1997; 82: 359–363.
155. Young ME, Radda GK, Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J. 1997; 322: 223–228.[Medline] [Order article via Infotrieve]
156. Cook S, Hugli O, Egli M, Menard B, Thalmann S, Sartori C, Perrin C, Nicod P, Thorens B, Vollenweider P, Scherrer U, Burcelin R. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes. 2004; 53: 2067–2072.
157. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension. 1998; 32: 3–8.
158. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O’Shaughnessy KM, Brown MJ. A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999; 100: 1515–1520.
159. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, Harada E, Masuda T, Koyama W, Saito Y, Miyamoto Y, Ogawa Y, Nakao K. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. 1998; 31: 1506–1510.
160. Cai H, Wilcken DE, Wang XL. The Glu-298->Asp (894G->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med. 1999; 77: 511–514.[CrossRef][Medline] [Order article via Infotrieve]
161. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996; 2: 41–45.[CrossRef][Medline] [Order article via Infotrieve]
162. Shoji M, Tsutaya S, Saito R, Takamatu H, Yasujima M. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci. 2000; 66: 2557–2562.[CrossRef][Medline] [Order article via Infotrieve]
163. Ohtoshi K, Yamasaki Y, Gorogawa S, Hayaishi-Okano R, Node K, Matsuhisa M, Kajimoto Y, Hori M. Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance. Diabetologia. 2002; 45: 1594–1601.[CrossRef][Medline] [Order article via Infotrieve]
164. Sartori C, Scherrer U. Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. J Hypertens. 1999; 17: 1517–1525.[Medline] [Order article via Infotrieve]
165. Monti LD, Barlassina C, Citterio L, Galluccio E, Berzuini C, Setola E, Valsecchi G, Lucotti P, Pozza G, Bernardinelli L, Casari G, Piatti P. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes. 2003; 52: 1270–1275.
This article has been cited by other articles:
 |
|
 |
|
  A. Csiszar, N. Labinskyy, J. T. Pinto, P. Ballabh, H. Zhang, G. Losonczy, K. Pearson, R. de Cabo, P. Pacher, C. Zhang, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H13 - H20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hui, W. Zhu, Y. Wang, K. S. L. Lam, J. Zhang, D. Wu, E. W. Kraegen, Y. Li, and A. Xu Major Urinary Protein-1 Increases Energy Expenditure and Improves Glucose Intolerance through Enhancing Mitochondrial Function in Skeletal Muscle of Diabetic Mice J. Biol. Chem., May 22, 2009; 284(21): 14050 - 14057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rao, L. Li, C. Demello, D. Guo, B. L. Jaber, B. J.G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Mitochondrial DNA Injury and Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., January 1, 2009; 20(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Addabbo, B. Ratliff, H.-C. Park, M.-C. Kuo, Z. Ungvari, A. Ciszar, B. Krasnikof, K. Sodhi, F. Zhang, A. Nasjletti, et al. The Krebs Cycle and Mitochondrial Mass Are Early Victims of Endothelial Dysfunction: Proteomic Approach Am. J. Pathol., January 1, 2009; 174(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Wilcox and A. Pearlman Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ventura-Clapier, A. Garnier, and V. Veksler Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha} Cardiovasc Res, July 15, 2008; 79(2): 208 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Konstantinova, G. S. Tell, S. E. Vollset, O. Nygard, O. Bleie, and P. M. Ueland Divergent Associations of Plasma Choline and Betaine with Components of Metabolic Syndrome in Middle Age and Elderly Men and Women J. Nutr., May 1, 2008; 138(5): 914 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ungvari, N. Labinskyy, S. Gupte, P. N. Chander, J. G. Edwards, and A. Csiszar Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2121 - H2128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, Y. Wei, and J. R. Sowers Role of Mitochondrial Dysfunction in Insulin Resistance Circ. Res., February 29, 2008; 102(4): 401 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kashyap, A. Lara, R. Zhang, Y. M. Park, and R. A. DeFronzo Insulin Reduces Plasma Arginase Activity in Type 2 Diabetic Patients Diabetes Care, January 1, 2008; 31(1): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Whitsett, M. J. Picklo Sr, and J. Vasquez-Vivar 4-Hydroxy-2-Nonenal Increases Superoxide Anion Radical in Endothelial Cells via Stimulated GTP Cyclohydrolase Proteasomal Degradation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2340 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Singer Powering Up Failed Organs Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 733 - 734. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sookoian and C. J. Pirola Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 37 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||